It happens in glioblastoma through upregulation or a gain-of-function mutation of receptor tyrosine kinases (RTKs), such as epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR) [3,4]. The gene discussed is EGFR; the disease is glioblastoma.